NCT00005622View on ClinicalTrials.gov

Donor Bone Marrow Transplant in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders

PHASE2CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

May 31, 1996

Primary Completion Date

September 30, 2005

Study Completion Date

July 31, 2009

Conditions
Chronic Myeloproliferative DisordersLeukemiaMultiple Myeloma and Malignant Plasma Cell NeoplasmsMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Neoplasms
Interventions
DRUG

cyclophosphamide

Cyclophosphamide is administered at a dose of 60 mg/kg on each of two successive days (Days -6 and -5)

RADIATION

TBI

FTBI is performed on day -3 through day 0 The total dose of radiation is 1,320 cGy.

Trial Locations (1)

33612-9497

Moffitt Cancer Center, Tampa

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER

NCT00005622 - Donor Bone Marrow Transplant in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders | Biotech Hunter | Biotech Hunter